Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials

Journal of Trauma - Injury, Infection and Critical Care

Volumn 59, Issue 1, 2005, Pages 8-18

  Boffard, Kenneth David ^a   Riou, Bruno ^g   Warren, Brian ^b   Choong, Philip Iau Tsau ^c   Rizoli, Sandro ^d   Rossaint, Rolf ^e   Axelsen, Mads ^f   Kluger, Yoram ^g   Champion, Howard R ^g   Lucas, Charles ^g   Thompson, Errington ^g   Ross, Steve ^g   Jurkovich, Gregory J ^g   Lynn, Mauricio ^g   Pitts, Lawrence ^g   Croce, Martin A ^g  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f NOVO NORDISK A S   (Denmark)

^g PostNet ^*

Author keywords

Blood transfusion; Blunt trauma; Coagulopathy; Hemorrhage; Massive transfusion; Penetrating trauma; Recombinant factor VIIa; Trauma

Indexed keywords

PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLUNT TRAUMA; BRAIN INFARCTION; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INJURY; INTESTINE INFARCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MESENTERIC VEIN THROMBOSIS; MORTALITY; PENETRATING TRAUMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; ERYTHROCYTE TRANSFUSION; FACTOR VIIA; FEMALE; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 24644491444     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000171453.37949.B7     Document Type: Article

References (32)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269-1276.
2. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995;38:185-193.
3. Bellamy RF. The causes of death in conventional land warfare: implications for combat casualty care research. Mil Med. 1984; 149:55-62.
4. Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med. 2002;28(suppl 2):S241-S247.
5. Hoyt DB, Bulger EM, Knudson MM, et al. Death in the operating room: an analysis of a multi-center experience. J Trauma. 1994; 37:426-432.
6. Reiss RF. Hemostatic defects in massive transfusion: rapid diagnosis and management. Am J Crit Care. 2000;9:158-165.
7. Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg. 2002;68:566-572.
8. Sauaia A, Moore FA, Moore EE, et al. Early predictors of postinjury multiple organ failure. Arch Surg. 1994;129:39-45.
9. Moore FA, Moore EE, Sauaia A. Blood-transfusion: an independent risk factor for postinjury multiple organ failure. Arch Surg. 1997; 132:620-625.
10. O'Neill PA, Bluth M, Gloster ES, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma. 2002; 52:400-405.
11. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709-719.
12. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431-439.
13. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999; 354:1879.
14. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice, 01 May 1996, Geneva, Switzerland.
15. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-824.
16. Moore FA, Moore EE. Postinjury multiple organ failure. In: Moore EE, Feliciano DV, Mattox KL, eds. Trauma. New York: McGraw-Hill; 2004:1399-1400.
17. Riou B, Landais P, Vivien B, Stell P, Labbene I, Carli P. Distribution of the probability of survival is a strategic issue for randomized trials in critically ill patients. Anesthesiology. 2001; 95:56-63.
18. Hodges JL, Lehmann EL. Estimates of location based on rank tests. Ann Math Stat. 1963;34:598-611.
19. Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR. Blood transfusion rates in the care of acute trauma. Transfusion. 2004; 44:809-813.
20. Gubler KD, Gentilello LM, Hassantash SA, Maier RV. The impact of hypothermia on dilutional coagulopathy. J Trauma. 1994;36:847-851.
21. Bernabei AF, Levison MA, Bender JS. The effects of hypothermia and injury severity on blood loss during trauma laparotomy. J Trauma. 1992;33:835-839.
22. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331:1601-1606.
23. Gando S, Nanzaki S, Sasaki S, Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost. 1998;79:1111-1115.
24. Gando S, Nanzaki S, Morimoto Y, Kobayashi S, Kemmotsu O. Systemic activation of tissue-factor dependent coagulation pathway in evolving acute respiratory distress syndrome in patients with trauma and sepsis. J Trauma. 1999;47:719-723.
25. Gando S, Nanzaki S, Morimoto Y, Ishitani T, Kemmotsu O. Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients. Crit Care Med. 2001;29:262-266.
26. Gando S, Kameue T, Matsuda N, et al. Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma. Thromb Haemost. 2002;88:943-949.
27. Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S61-S65.
28. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-547.
29. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899-909.
30. Roberts H, Monroe DM, White GC. The clinical use of recombinant factor VIIa: a review. Blood. 2004;104;3858-3864.
31. Moore FA, Haenel JB, Moore EE, Whitehill TA. Incommensurate oxygen consumption in response to maximal oxygen availability predicts postinjury multiple organ failure. J Trauma. 1992;33:58-65.
32. Blow O, Magliore L, Claridge JA, Butler K, Young JS. The golden hour and the silver day: detection and correction of occult hypoperfusion within 24 hours improves outcome from major trauma. J Trauma. 1999;47:964-969.